Weekly NADAC archive
Every weekly executive brief is preserved as a dated snapshot so the editorial narrative, Top 10 movers, and supporting summaries stay consistent over time.
Archived editions
Latest edition count: 5. Use the latest page for the current brief and these dated pages for historical context.
NADAC weekly update: 14 NDCs changed — 2026-09-30
The CMS publication dated 2026-09-30 contains 30,079 priced NDCs in our data. Of the 29,945 NDCs also priced in the 2026-09-23 publication, 14 changed and 29,931 were unchanged. This edition reports the available updates; a small number of changes does not establish a market-wide trend.
NADAC Week of Sep 23: Biosimilar Surge Drives Cost Pressure While Broader Market Skews Lower
The September 23, 2026 NADAC release compared against September 16 shows a market with more line-item decreases (15,294) than increases (13,311) across 29,892 comparable NDCs, indicating a mild net downward bias in pricing activity despite a few large upside outliers. The standout event is a $3.0M weighted increase in Fulphila (pegfilgrastim-jmdb) from Biocon Biologics, which single-handedly drove the Leukocyte Growth Factor class to the top of this week's cost-pressure rankings and made Biocon the largest manufacturer swing. On the relief side, Kesimpta (ofatumumab) posted the largest single-product decline at $469.9K, while the Corticosteroid class—spanning 1,122 drugs—registered a modest but broad-based $436.6K decrease, reinforcing that downward movement this week is more widely distributed than the upside, which is concentrated in a handful of specialty biologics.
NADAC weekly update: no price changes among comparable NDCs — 2026-09-16
The CMS publication dated 2026-09-16 contains 29,936 priced NDCs in our data. Of the 29,915 NDCs also priced in the 2026-09-09 publication, 0 changed and 29,915 were unchanged. This edition reports the available updates; a small number of changes does not establish a market-wide trend.
NADAC weekly update: 3 NDCs changed — 2026-09-09
The CMS publication dated 2026-09-09 contains 29,922 priced NDCs in our data. Of the 29,903 NDCs also priced in the 2026-09-02 publication, 3 changed and 29,900 were unchanged. This edition reports the available updates; a small number of changes does not establish a market-wide trend.
NADAC Weekly Brief: AbbVie's Immunology Portfolio Drives Net Gains as Ustekinumab and Paliperidone Pull Prices Down
For the week ending August 19, 2026, NADAC pricing showed mixed movement across major therapeutic categories. AbbVie Inc. posted the largest aggregate manufacturer swing at $2.9M across 71 products, largely offsetting a $2.1M decline tied to Interleukin-12 Antagonist drugs (Ustekinumab). Risankizumab-rzaa led market-level gains at $2.7M (+0.3%), while Paliperidone Palmitate and Janssen-manufactured products registered notable declines. The Opioid Antagonist class emerged as the most pressured category, rising 1.2% and contributing $870.4K in impact across 107 drugs. Overall market movement remained tight, with most top-mover NDCs shifting less than 1% week-over-week.